Christiana I. Iwuagwu

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Christiana I. Iwuagwu is active.

Explore More

Publication

Featured researches published by Christiana I. Iwuagwu.

ACS Medicinal Chemistry Letters | 2017

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia

Dalton King; Christiana I. Iwuagwu; Jim Cook; Ivar M. McDonald; Robert A. Mate; F. Christopher Zusi; Matthew D. Hill; Haiquan Fang; Rulin Zhao; Bei Wang; Amy Easton; Regina Miller; Debra J. Post-Munson; Ronald J. Knox; Lizbeth Gallagher; Ryan Westphal; Thaddeus F. Molski; Jingsong Fan; Wendy Clarke; Yulia Benitex; Kimberley A. Lentz; Rex Denton; Daniel J. Morgan; Robert Zaczek; Nicholas J. Lodge; Linda J. Bristow; John E. Macor; Richard E. Olson

The therapeutic treatment of negative symptoms and cognitive dysfunction associated with schizophrenia is a significant unmet medical need. Preclinical literature indicates that α7 neuronal nicotinic acetylcholine (nACh) receptor agonists may provide an effective approach to treating cognitive dysfunction in schizophrenia. We report herein the discovery and evaluation of 1c (BMS-933043), a novel and potent α7 nACh receptor partial agonist with high selectivity against other nicotinic acetylcholine receptor subtypes (>100-fold) and the 5-HT3A receptor (>300-fold). In vivo activity was demonstrated in a preclinical model of cognitive impairment, mouse novel object recognition. BMS-933043 has completed Phase I clinical trials.

Archive | 2009

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

H. Cook Ii James; Ivar M. McDonald; Dalton King; Richard E. Olson; Nenghui Wang; Christiana I. Iwuagwu; F. Christopher Zusi; John E. Macor

PLOS ONE | 2016

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.

Linda J. Bristow; Amy Easton; Yu-Wen Li; Digavalli V. Sivarao; Regina Lidge; Kelli M. Jones; Debra J. Post-Munson; Christopher Daly; Nicholas J. Lodge; Lizbeth Gallagher; Thaddeus F. Molski; Richard Pieschl; Ping Chen; Adam Hendricson; Ryan Westphal; James M. Cook; Christiana I. Iwuagwu; Daniel J. Morgan; Yulia Benitex; Dalton King; John E. Macor; Robert Zaczek; Richard K. Olson

Journal of Medicinal Chemistry | 2016

Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship

James M. Cook; F. Christopher Zusi; Ivar M. McDonald; Dalton King; Matthew D. Hill; Christiana I. Iwuagwu; Robert A. Mate; Haiquan Fang; Rulin Zhao; Bei Wang; Jingfang Qian Cutrone; Baoqing Ma; Qi Gao; Ronald J. Knox; Michele Matchett; Lizbeth Gallagher; Meredith Ferrante; Debra J. Post-Munson; Thaddeus F. Molski; Amy Easton; Regina Miller; Kelli M. Jones; Siva Digavalli; Francine Healy; Kimberley A. Lentz; Yulia Benitex; Wendy Clarke; Joanne Natale; Judith A. Siuciak; Nicholas J. Lodge

Archive | 2011

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

Kimberley A. Lentz; Rex Denton; James Cook; Ivar M. McDonald; Dalton King; Richard E. Olson; Nenghui Wang; Robert A. Mate; Christiana I. Iwuagwu; F. Christopher Zusi; John E. Macor; Matthew D. Hill; Haiquan Fang

ACS Medicinal Chemistry Letters | 2017

Development of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists

Matthew D. Hill; Haiquan Fang; H. Dalton King; Christiana I. Iwuagwu; Ivar M. McDonald; James Cook; F. Christopher Zusi; Robert A. Mate; Ronald J. Knox; Debra J. Post-Munson; Amy Easton; Regina Miller; Kimberley A. Lentz; Wendy Clarke; Yulia Benitex; Nicholas J. Lodge; Robert Zaczek; Rex Denton; Daniel J. Morgan; Linda J. Bristow; John E. Macor; Richard E. Olson

Bioorganic & Medicinal Chemistry Letters | 2017

Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR

Christiana I. Iwuagwu; Dalton King; Ivar M. McDonald; James Cook; F. Christopher Zusi; Matthew D. Hill; Robert A. Mate; Haiquan Fang; Ronald J. Knox; Lizbeth Gallagher; Debra Post-Munson Amy Easton; Regina Miller; Yulia Benitex; Judy Siuciak; Nicholas J. Lodge; Robert Zaczek; Daniel G. Morgan; Linda J. Bristow; John E. Macor; Richard E. Olson

Archive | 2010

Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands

Ivar M. McDonald; Robert A. Mate; H. Cook Ii James; Dalton King; Richard E. Olson; Nenghui Wang; Christiana I. Iwuagwu; F. Christopher Zusi; Matthew D. Hill; Haiquan Fang; John E. Macor

Archive | 2009

Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands

H. Cook Ii James; Ivar M. McDonald; Dalton King; Richard E. Olson; Nenghui Wang; Christiana I. Iwuagwu; F. Christopher Zusi; John E. Macor

Archive | 2010

Composés d'azabicyclo[2.2.1]heptane en tant que ligands du récepteur alpha-7 nicotinique d'acétylcholine

Ivar M. McDonald; Robert A. Mate; Ii James H. Cook; Dalton King; Richard E. Olson; Nenghui Wang; Christiana I. Iwuagwu; F. Christopher Zusi; Matthew D. Hill; Haiquan Fang; John E. Macor

Explore More